Research - A $200 million market capitalization. $340 million in cash and equivalents. Negative enterprise value of $130 million. Down 90% over the last 6 months. Not many publicly traded companies fit this description.
Premium: Read NowResearch - Put simply, appetites for healthcare equities are in short supply, and as we’ve been discussing, it makes sense to be prepared for a reversion to the mean for the sector. This has been/is slowly playing out.
Premium: Read NowResearch - Equities remain linked at the hip to the fluctuations in oil, and Thursday marked the first meaningful decoupling in the last month. According to the Wall Street Journal, over the past 20 trading days (one month) the correlation has been 0.97, the highest in 26 years.
Premium: Read NowEducation - Oil has yet to stabilize and investors are skittish about a rising interest rate environment; it's the first since 2004. China's economy is slowing, and their markets have tanked over the last few months. These are why equities can't find a bottom, according to the financial press, anyway.
Premium: Read NowResearch - Today marked day two of the JP Morgan Healthcare investing conference, and biotech stocks still couldn’t catch a bid until late this afternoon. The mood … Continue Reading
Premium: Read NowResearch - UniQure’s (QURE) AAV5-enabled AMT-060 looks good in its first human testing to date, with four of five Hemophilia B patients in the low-dose cohort fully … Continue Reading
Read NowInsights - Biopharma stocks are starting the year off on absolutely the wrong foot (though so is everything else), and last night’s SEVEN secondary stock offerings didn’t help Wednesday's price action.
Premium: Read Now
